Morbid Obesity
Conditions
Keywords
morbid obesity, BMI at or above 4O kg/m2, ingestion of omega 3, inflammatory cytokines, biochemical factors, anthropometric factors
Brief summary
Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly obese patients, will improve the inflammatory status? C-reactive protein? Weight?
Detailed description
Intake of EPA and DHA for the management of morbid obesity in capsules \- Reduction of inflammatory factors such as adipokines, glucose, C-reactive protein, cholesterol, weight, BMI. Will be 2 groups: cases and controls. The cases will intake of omega 3 capsules and placebo control.
Interventions
DIETARY_SUPPLEMENTOmega 3 intake, morbid obesity
Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
DIETARY_SUPPLEMENTPlacebo Capsules
They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
Sponsors
Pontificia Universidade Católica do Rio Grande do Sul
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Men and women aged between 18-65 years, * BMI \> 40 kg/m2 (or \> 35 kg/m2 with comorbidities), * ambulatory, receiving an oral diet, * with a diagnosis of metabolic syndrome, * and who signed a Term of Free and Informed Consent.
Exclusion criteria
* Systemic inflammatory response syndrome, * coma or compromised organ, * fever or infection foci, * cancer with or without chemotherapy and radiotherapy, * radiotherapy, inflammatory diseases of the gastrointestinal tract, * transplant, trauma, surgery or hospital stay in the past 30 days * use of steroids or non-steroid anti-inflammatory or immunomodulators agents or antibiotics, * or those refusing to take part in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease of inflammatory levels on blood | 08 weeks | expected from this study verify inflammatory factors such as adipokines, glucose, c reactive protein, lipid profile, triglycerides, and anthropometric data as visceral fat, weight, BMI, in both groups, control and intervention, to see the action of the capsules of omega 3.patient may withdraw any time from ingestion of capsules, and the same will be provided by the laboratory Vitamed, which is regularized with the supervisory bodies and food security of Brazil |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Decrease of weight | 08 weeks | The weight will be measured before and after the intake of omega 3. |
Outcome results
None listed